Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a 'Buy' rating on Taysha Gene Therapies (NASDAQ:TSHA), but has lowered the price target from $7 to $6.
September 20, 2023 | 1:52 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity has maintained a 'Buy' rating on Taysha Gene Therapies but lowered the price target from $7 to $6.
The news is directly about Taysha Gene Therapies. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100